Is ImageneBio Inc halal to invest in?

According to Musaffa's Shariah screening methodology, ImageneBio Inc (IMA) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is ImageneBio Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes ImageneBio Inc using these criteria to determine its compliance status.

Can Muslims buy shares of ImageneBio Inc?

Muslim investors may consider investing in ImageneBio Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is ImageneBio Inc classified as NOT HALAL?

Musaffa determines the Shariah status of ImageneBio Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for ImageneBio Inc updated?

The Shariah compliance status of ImageneBio Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like ImageneBio Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of ImageneBio Inc?

You can check the latest Shariah compliance status of ImageneBio Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

IMA Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 12, 2026

Report Source: 2025 Annual Report

ImageneBio Inc. Stock Analysis IMA

United States Health Care Micro Cap Report: 2025 Annual

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. The company is headquartered in San Diego, California and currently employs 15 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The firm develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The firm is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.

Key Statistics of ImageneBio Inc (IMA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$5.58$5.86

Today's Open

$5.86

Volume

16.26K

P/E Ratio (TTM)

52 Week Range

$3.94$18.00

Market Cap

65.21M

Avg. Volume

72.66K

Dividend Yield

Financial Metrics & Statements of ImageneBio Inc (IMA)

FAQ's for ImageneBio Inc (IMA)

According to Musaffa’s Shariah screening methodology, ImageneBio Inc (IMA) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.